Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study

Proof of concept study of sequential ONCOS-102 then pembrolizumab treatment in patients with advanced melanoma refractory to check-point inhibitors Oslo 10 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the first patient has been recruited in the Company's ONCOS-102 study in advanced or unresectable melanoma patients who have had progression following checkpoint inhibitor. The study is conducted at Memorial Sloan Kettering Cancer Center in New York. Anne-

Etrion Releases First Quarter 2017 Results

May 10, 2017, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three months ended March 31, 2017.   Operational Highlights · Japan project development: Advanced on the development of the Kumamoto project in Japan with a total capacity of 45 megawatts (“MW”). Management expects to reach financial close for this backlog project in the fourth quarter of 2017. The Company is

AcadeMedia’s interim report July 2016 - March 2017

Third quarter (Jan 2017 – March 2017) · Net sales increased by 9.7 percent to SEK 2,540 million (2,316). · Operating profit (EBIT) decreased slightly to SEK 195 million (196). Adjusted for items affecting comparability, operating profit was SEK 197 million (199). · Net profit for the period was SEK 132 million (129). · Cash flow from operating activities amounted to SEK 123 million (128). · The average number of children and students in preschool, compulsory school and upper secondary school during the quarter was 66,299 (63,716), representing an increase of 4.1 percent.

Interim Report

January 1 – March 31, 2017The first quarter in figures · Net sales amounted to TSEK 1,755 (1,066). · The loss after tax amounted to TSEK 11,612 (11,600). · The loss per share amounted to SEK 1.40 (1.40). · The cash flow from current operations was negative in the amount of TSEK 11,981 (11,247). · The gross margin in the period was 26.5% (26.3%). Important events during the quarter · Our primary market Germany continues to show good growth with sales in value up by 99% and electrode sales volume up by 95% in the quarter. · Significant resources invested in the PMA

Notice to attend the Annual General Meeting of Shareholders of DDM Holding AG

The shareholders of DDM Holding AG (First North: DDM), (the “Company”), are hereby convened to the 2017 Annual General Meeting (the “AGM”) to be held on Wednesday, 31 May 2017 at 9:00 a.m. CEST, at the offices of Walder Wyss Ltd, Seefeldstr. 123, 8008 Zurich, Switzerland. The doors will open at 8:30 a.m. CEST.The shareholders are cordially invited to review the various ways to participate at the AGM and cast their vote. Detailed information on this and the agenda items can be found in the attached invitation to the AGM, also available on the Company’s website, http://ddm-group.ch/investors.

Nexam Chemical Holding AB (publ) Interim Financial Report 1 January – 31 March 2017

Solid base for growth in PET-foamFirst quarter at a glance Operational: · Supply agreement signed with Armacell regarding the NEXAMITE®-technology and related products for the production of PET-based foam. · Additional outsourcing concerning volume production of masterbatch at a new contract manufacturer. Financials: · Net sales for the first quarter totaled SEK 2,336,000 (816,000). · The operating loss for the firsts quarter SEK -4,933,000 (-4,706,000). · In comparison to the beginning of the year, cash and cash equivalents amounted to SEK 124,785,000 (133,147,000).

Wilson Therapeutics to host conference call to provide first quarter 2017 business update

On May 17, 2017, at 08:00 CET, Wilson Therapeutics will publish its interim report for the first quarter 2017. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 10:00 CET. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf, and the presentation will be held in English. How to participateThe live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q1-2017.

INTERIM REPORT JANUARY – MARCH 2017

FIRST QUARTER ·  Net sales amounted to MSEK 139.3 (82.3), equivalent to an increase of 69.3%. Growth was mainly due to acquisitions. ·  EBITDA amounted to MSEK 43.7 (9.3), which corresponds to a margin of 31.4% (11.3%) ·  Cash flow from operating activities amounted to MSEK 34.9 (-61.0) ·  Earnings per share was SEK 0.29 (0.05) ·  Cash and cash equivalents and other short-term investments at the end of the period amounted to MSEK 166.1 (11.2) ·  A rights issue raised a total of MSEK 374 SIGNIFICANT EVENTS AFTER PERIOD END · Pfizer pays a milestone of MUSD 2 ·

Swedbank acquires PayEx

Swedbank acquires the payment provider PayEx. Through the acquisition Swedbank enters a new market and add services to meet customers’ needs of digital solutions for payments.The market for payment solutions has undergone major changes in recent years by greatly increased on-line purchases and development of invoicing solutions. Payment Service Providers (PSP), as PayEx, has been established with the purpose to improve the purchase experience. The acquisition creates good prerequisites to continue to develop long term and attractive payment solutions for retail businesses and its

AZ updates on tralokinumab trial in severe asthma

This announcement contains inside information   10 May 2017 07:00 BST ASTRAZENECA PROVIDES UPDATE ON STRATOS 1 PHASE III TRIAL OF TRALOKINUMAB IN SEVERE, UNCONTROLLED ASTHMA Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017     AstraZeneca and MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its

1A SMART START, LLC ANNOUNCES A RECOMMENDED OFFER OF SEK 11.30 PER SHARE TO THE SHAREHOLDERS OF DIGNITA SYSTEMS AB

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of

Notice of an extraordinary general meeting

Notice is hereby served that an extraordinary general meeting of MPC Container Ships AS (the "Company") will be held on 18 May 2017 at 10.00 hours at the offices of Fearnley Business Management AS, Grev Wedels plass 9, 0151 Oslo, Norway. Agenda: 1. Election of a chairperson and a person to countersign the minutes 2. Approval of the notice and the agenda 3. Election of board of directors 4. Election of the auditor Shareholders who will attend the meeting (in person or by proxy) are requested to notify the Company of this by sending the attendance form to MPC CONTAINER SHIPS AS c/

Hexagon Composites ASA: Results for the first quarter 2017

In the first quarter 2017 Hexagon Composites generated NOK 346.2 (291.6) million in operating income and made an operating profit before depreciation (EBITDA) of NOK 35.1 (18.6) million. Operating profit (EBIT) was NOK 16.6 (3.2) million and profit/loss before tax came to NOK 6.3 (-2.6) million. The financial statements for the first quarter 2017 include the Group's fifty-percent share of Agility Fuel Solutions results accounted for under the equity method. In addition, the fully consolidated financial results of the acquired xperion Energy & Environment ("xperion") and related group

CXENSE ASA ANNOUNCES FIRST QUARTER 2017 RESULTS

OSLO, NORWAY – MAY 10, 2017 - CXENSE ASA TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDING MARCH 31, 2017. Highlights: · Data management and personalization revenue of USD 4.3 million, up 21% year-over-year · High Q1 churn driven by one large acquired video customer and continued decline of advertising portfolio · Q1 2017 group revenue of USD 5.9 million, down 5.5% year-over-year due to churn · EBITDA reflects continued investments in growth · Strategic investments in partners mporium and RepKnight to strengthen Cxense’s offering, distribution and sales ·

2017 guidance raised based on strong revenue growth and improved profitability

HIGHLIGHTS· Revenue reached DKK 4,211 million in the first quarter of 2017 representing an increase of 12% compared to the same period last year · Revenue in North America increased by 21% to DKK 2,437 million (21% in local currency) · Revenue in International Markets increased by 6% to DKK 991 million (3% in local currencies) · Revenue in Europe decreased by 5% to DKK 709 million (6% decline in local currencies) · Revenue from key products grew 46% (46% in local currencies) to DKK 1,980 million in the period representing 47% of total revenue · Revenue of Abilify

Elekta appoints Gustaf Salford as Chief Financial Officer

STOCKHOLM, May 10, 2017– Elekta (EKTA-B.ST) announced today that Gustaf Salford has been appointed Executive Vice President and Chief Financial Officer effective July 1, 2017, succeeding Håkan Bergström, who will retire per the same date.Salford joined Elekta in 2009 and has worked in several financial leadership roles within the company, most recently as Head of Group Business Control. In addition to an MSc degree in Business Administration from the Stockholm School of Economics, Salford brings broad financial experience from among others Boston Consulting Group and Booz Allen Hamilton, as

Scandic’s interim report Q1 2017 – Continued strong underlying growth

First quarter in summary · Net sales increased by 19.3% to 3,095 MSEK (2,594) due to higher RevPAR, more rooms in operation and positive currency effects. · RevPAR LFL grew by 12.2% driven by higher occupancy and increased average room rates. · The Easter holiday fell entirely in April which is why the quarter is not fully comparable with the first quarter 2016. Calendar effects are estimated to have had a positive impact on net sales- and RevPAR growth for comparable units of 7 percentage points. · Adjusted EBITDA increased to 154 MSEK (40), corresponding to a margin of 5.0% (

Interim report January - March 2017

1 January - 31 March 2017 ● Revenue increased 7 per cent to SEK 1,518 M (1,424). Adjusted for currency effects and calculated on the comparable number of workdays, revenue decreased 3 per cent. Sales in comparable units rose 5 per cent.● EBITA increased to SEK 155 M (149) and the EBITA margin amounted to 10 per cent (10).● EBIT increased to SEK 126 M (121) and the EBIT margin was 8 per cent (9).● The gross margin amounted to 53.6 per cent (54.2).● Earnings per share, before and after dilution, rose to SEK 2.33 (2.28).● Cash flow from operating activities rose to SEK 37 M (30).

Interim report January–March 2017

January–March 2017 · Net sales increased by 20% to SEK 4,115 million (3,427) · Organic growth was 12% (-3) · The order backlog increased by 26% to SEK 9,000 million (7,135) · Operating profit increased by 19% to SEK 209 million (175) · The operating margin was 5.1% (5.1) · Profit after tax was SEK 151 million (123) · Cash flow from operating activities was SEK 381 million (13) · Net debt amounted to SEK 2,058 million (2,416) · Earnings per share were SEK 0.75 (0.61) CEO statement “Strong organic growth and strong cash flow” Organic growth supported by

Raisio plc's Interim Report January-March 2017: Raisio’s comparable EBIT totalled EUR 10.6 million

Raisio plc        Interim Report 10 May 2017 at 8:30 a.m. Finnish time RAISIO’S COMPARABLE EBIT TOTALLED EUR 10.6 MILLION January-March 2017 · The Group’s comparable EBIT totalled EUR 10.6 million (Q1/2016: EUR 9.7 million), accounting for 11.4% (8.5%) of net sales. · The Group’s net sales totalled EUR 92.5 million (EUR 114.0 million). · EBIT of the Brands Division was EUR 12.0 million (EUR 11.4 million),accounting for 16.6% (12.6%) of net sales. · Raisioagro’s EBIT was EUR -0.3 million (EUR 0.0 million).   CEO JARMO PUPUTTI’S REVIEW  “Raisio’s comparable EBIT

Interim Report 1 January – 31 March 2017

3 months ended 31 March 2017 · Local currency sales increased by 8% and Euro sales increased by 11% to €340.1m (€305.8m). · Number of registered actives decreased by 4% to 3.0m. · EBITDA amounted to €40.4m (€27.7m). · Operating margin was 8.8% (6.9%), favourably impacted by 90 bps from currencies, and operating profit was €29.8m (€21.1m). · Net profit increased to €19.5m (€10.7m) and diluted EPS €0.34 (€0.19). · Cash flow from operating activities was €-1.5m (€21.5m). · The year to date sales development is approximately 9% in local currency and the development in the

Navamedic ASA: Q1 2017 results

Oslo, 10 May 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 78.2 million in the first quarter of 2017 (NOK 60.8 million in Q1 2016), representing a growth of 28.6%, in part due to a widened distribution across new European markets under the partnership with TopRidge Pharma. The Sippi® commercialisation continues to be on a good track and the company expects to enter an accelerated growth path towards the long-term revenue potential of the proprietary urine measurement system. "Navamedic had a solid first quarter in 2017, with overall revenues up 28.6 percent compared to the

There are no items matching the current filter
There are no more items matching the current filter
Back to top